ACR-FDA Summit
About the Event
Date:2024 | To Be Announced
Location:Location To Be Announced
Credit:CME/MOC TBA
On Demand:Not Available
Registration Coming Soon
This summit addresses patient care, policy, and research-relevant topics on the assessment of long-term safety, clinical efficacy, and structural outcomes in conjunction with novel study designs and biomarkers development in the field of rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
Conducting clinical trials in these areas has become complex and challenging because prolonged placebo use is no longer appropriate or acceptable control to the community and patients. Respectively, stakeholders in both academia and industry are faced with challenges related to the development of efficient, feasible, and ethical RCT designs as they focus on less toxic and more durable regimens for rheumatology patients with RA or PsA.
The ACR-FDA Summit is an interactive, consensus building format that brings together various stakeholders from academia and industry to provide a broad perspective on current clinical development challenges while offering practical means to overcome these challenges.
Program Schedule
Coming Soon
Registration Fees
Coming Soon
CME
Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
See the ACR’s CME Mission Statement. For more information, download the AMA PRA Booklet.
Designation Statement
The ACR designates this virtual activity for a maximum of (to be announced) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC
MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to (to be announced) MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.
See information from the 2022 ACR-FDA Summit.
Target Audience
Rheumatologists, physicians, clinicians, healthcare providers who care for patients with rheumatic diseases, and those interested or engaged in clinical research.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss ways to maintain interest in RA and PsA drug development
- Review innovative study designs, including use of novel outcome measures and patient reported outcomes (PROs)